Log in
NASDAQ:ARQT

I-Mab Stock Forecast, Price & News

$17.82
-2.22 (-11.08 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$17.53
Now: $17.82
$21.19
50-Day Range
$20.04
MA: $24.35
$31.04
52-Week Range
$17.10
Now: $17.82
$40.88
Volume296,517 shs
Average Volume325,380 shs
Market Capitalization$680.55 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARQT
CUSIPN/A
CIKN/A
Phone805-418-5006
Employees27

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$680.55 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$17.82
-2.22 (-11.08 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARQT News and Ratings via Email

Sign-up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











I-Mab (NASDAQ:ARQT) Frequently Asked Questions

How has I-Mab's stock price been impacted by COVID-19?

I-Mab's stock was trading at $25.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARQT stock has decreased by 28.7% and is now trading at $17.82.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of I-Mab?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for I-Mab
.

When is I-Mab's next earnings date?

I-Mab is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for I-Mab
.

How were I-Mab's earnings last quarter?

I-Mab (NASDAQ:ARQT) announced its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.94) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.84) by $0.10.
View I-Mab's earnings history
.

What price target have analysts set for ARQT?

5 brokerages have issued 12-month price targets for I-Mab's shares. Their forecasts range from $30.00 to $55.00. On average, they anticipate I-Mab's stock price to reach $41.80 in the next twelve months. This suggests a possible upside of 134.6% from the stock's current price.
View analysts' price targets for I-Mab
.

Who are some of I-Mab's key competitors?

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include I-Mab (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

Who are I-Mab's key executives?

I-Mab's management team includes the following people:
  • Mr. Todd Franklin Watanabe, Pres, CEO & Director (Age 51)
  • Dr. Bhaskar Chaudhuri, Co-Founder & Independent Director (Age 65)
  • Mr. John W. Smither, Chief Financial Officer (Age 67)
  • Dr. David W. Osborne, Chief Technical Officer (Age 59)
  • Mr. Keith L. Klein, Gen. Counsel & Sec. (Age 56)

When did I-Mab IPO?

(ARQT) raised $125 million in an IPO on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager.

What is I-Mab's stock symbol?

I-Mab trades on the NASDAQ under the ticker symbol "ARQT."

How do I buy shares of I-Mab?

Shares of ARQT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is I-Mab's stock price today?

One share of ARQT stock can currently be purchased for approximately $17.82.

How big of a company is I-Mab?

I-Mab has a market capitalization of $680.55 million. The company earns $-42,000,000.00 in net income (profit) each year or ($22.78) on an earnings per share basis. I-Mab employs 27 workers across the globe.

What is I-Mab's official website?

The official website for I-Mab is www.arcutis.com.

How can I contact I-Mab?

I-Mab's mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The company can be reached via phone at 805-418-5006 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.